Page 90 - GTM-4-2

Global Translational Medicine Angiotensinogen in liver steatosis

and metabolic diseases. Arterioscler Thromb Vasc Biol. 25. Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package
2024;44:1021-1030. for comparing biological themes among gene clusters.
doi: 10.1161/ATVBAHA.124.318374 OMICS. 2012;16:284-287.
14. Tao XR, Rong JB, Lu HS, et al. Angiotensinogen in doi: 10.1089/omi.2011.0118
hepatocytes contributes to Western diet-induced liver 26. Tang D, Chen M, Huang X, et al. SRplot: A free online
steatosis. J Lipid Res. 2019;60:1983-1995. platform for data visualization and graphing. PLoS One.
doi: 10.1194/jlr.M093252 2023;18:e0294236.
15. Ye D, Wu C, Cai L, et al. Antisense oligonucleotides targeting doi: 10.1371/journal.pone.0294236
hepatic angiotensinogen reduce atherosclerosis and liver 27. Gaemers IC, Stallen JM, Kunne C, et al. Lipotoxicity and
steatosis in hypercholesterolemic mice. Glob Transl Med. steatohepatitis in an overfed mouse model for non-alcoholic
2023;2:288. fatty liver disease. Biochim Biophys Acta. 2011;1812:447-458.
doi: 10.36922/gtm.288 doi: 10.1016/j.bbadis.2011.01.003
16. Dutta S, Sengupta P. Men and mice: Relating their ages. Life 28. Spooner MH, Garcia-Jaramillo M, Apperson KD,
Sci. 2016;152:244-248. Lohr CV, Jump DB. Time course of western diet (WD)
doi: 10.1016/j.lfs.2015.10.025 induced nonalcoholic steatohepatitis (NASH) in female and
male Ldlr-/-mice. PLoS One. 2023;18:e0292432.
17. Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A guide
to non-alcoholic fatty liver disease in childhood and doi: 10.1371/journal.pone.0292432
adolescence. Int J Mol Sci. 2016;17:947. 29. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.
doi: 10.3390/ijms17060947 AASLD Practice Guidance on the clinical assessment and
management of nonalcoholic fatty liver disease. Hepatology.
18. Boyraz M, Hatipoglu N, Sari E, et al. Non-alcoholic
fatty liver disease in obese children and the relationship 2023;77:1797-1835.
between metabolic syndrome criteria. Obes Res Clin Pract. doi: 10.1097/HEP.0000000000000323
2014;8:e356-363.
30. Milic S, Stimac D. Nonalcoholic fatty liver disease/
doi: 10.1016/j.orcp.2013.08.003 steatohepatitis: Epidemiology, pathogenesis, clinical
presentation and treatment. Dig Dis. 2012;30:158-162.
19. Berardis S, Sokal E. Pediatric non-alcoholic fatty liver
disease: An increasing public health issue. Eur J Pediatr. doi: 10.1159/000336669
2014;173:131-139.
31. Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic
doi: 10.1007/s00431-013-2157-6 fatty liver disease: Clinical features and pathogenesis.
20. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. Gastroenterol Hepatol (N Y). 2006;2:282-291.
A position statement on NAFLD/NASH based on the EASL 32. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic
2009 special conference. J Hepatol. 2010;53:372-384. fatty liver disease. World J Gastroenterol. 2010;16:5286-5296.
doi: 10.1016/j.jhep.2010.04.008 doi: 10.3748/wjg.v16.i42.5286
21. Team RC. R: A language and environment for statistical 33. Khoonsari M, Mohammad Hosseini Azar M, Ghavam R,
computing. R Foundation for Statistical Computing; 2021. et al. Clinical manifestations and diagnosis of nonalcoholic
Available from : https://www.r-project.org [Last accessed on fatty liver disease. Iran J Pathol. 2017;12:99-105.
2022 Dec 16].
34. Li X, Wang Z, Klaunig JE. Modulation of xenobiotic nuclear
22. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A receptors in high-fat diet induced non-alcoholic fatty liver
Bioconductor package for differential expression analysis of disease. Toxicology. 2018;410:199-213.
digital gene expression data. Bioinformatics. 2010;26:139-140.
doi: 10.1016/j.tox.2018.08.007
doi: 10.1093/bioinformatics/btp616
35. Park WJ, Song JH, Kim GT, Park TS. Ceramide and
23. Carlson M. Genome wide annotation for Mouse. R package sphingosine 1-phosphate in liver diseases. Mol Cells.
version 3.14.0; 2021. Available from: https://bioconductor. 2020;43:419-430.
org/packages/release/data/annotation/html/org.Mm.eg.
db.html [Last accessed on 2021 Jun 15]. doi: 10.14348/molcells.2020.0054
24. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal 36. Al-Rashed F, Arefanian H, Madhoun AA, et al. Neutral
enrichment tool for interpreting omics data. Innovation sphingomyelinase 2 inhibition limits hepatic steatosis and
(Camb). 2021;2:100141. inflammation. Cells. 2024;13:463.
doi: 10.1016/j.xinn.2021.100141 doi: 10.3390/cells13050463

Volume 4 Issue 2 (2025) 82 doi: 10.36922/gtm.6027